<DOC>
	<DOCNO>NCT01055067</DOCNO>
	<brief_summary>This multicenter , single-arm study safety efficacy .</brief_summary>
	<brief_title>ARQ 197 Subjects With Relapsed Refractory Germ Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Seminoma</mesh_term>
	<criteria>1 . Histologicallyconfirmed nonCNS GCT , seminoma nonseminomas allow . 2 . Male subject 16 year age old . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status equal less 1 . 4 . Documented progression follow equal great 1 prior platinumcontaining chemotherapy regimen ( ) ( limit number line prior treatment ) , consider platinumresistant Investigator . Subjects progress whose tumor recur stem cell transplantation also allow . 5 . All subject must either decline candidate curative therapy . In general , mean subject would progressive disease ( PD ) receive highdose chemotherapy , certain feature make ineligible highdose chemotherapy , refuse highdose chemotherapy despite informed curative potential . 6 . Subjects must radiographically measurable disease define RECIST 1.1 meet one follow criterion : Documented germ cell tumor progression base radiographic measurement ; Elevated serum tumor marker case radiographically measure stable disease . 7 . Subjects able provide write informed consent , comply protocol visit procedure , able take oral medication , active infection chronic comorbidity would interfere therapy . 8 . Subjects must agree use doublebarrier contraceptive measure avoidance intercourse study 90 day last dose study drug . 9 . Adequate bone marrow , liver , renal function , define : Platelet count equal great 75 time 10^9/L ; Hemoglobin equal great 9.0 g/dL ; Absolute neutrophil count ( ANC ) equal great 1.5 time 10^9/L ; Total bilirubin equal less 2.5 mg/dL ; Alanine aminotransaminase ( ALT ) aspartate aminotransaminase ( AST ) equal less 2.5 time upper limit normal ( ULN ) ( equal le 5 time ULN subject liver metastasis ) ; Serum creatinine equal less 1.5 time ULN . 10 . Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date Independent Ethics Committee Institutional Review Board approve inform consent form ( include Health Insurance Portability Accountability Act authorization , applicable ) performance study specific procedure test . 1 . Previous concurrent cancer distinct GCT primary site histology , EXCEPT treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) . Any cancer curatively treat equal great 3 year prior enrollment permit . 2 . History cardiac disease : Congestive heart failure define Class II IV per New York Heart Association classification . Active coronary artery disease . Previously diagnose bradycardia cardiac arrhythmia define equal great Grade 2 accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , version 4.0 , uncontrolled hypertension . Myocardial infarction occur within 6 month prior study entry ( myocardial infarction occur great 6 month prior study entry permit ) . 3 . Active clinically serious infection ( ) define equal great Grade 2 accord NCI CTCAE , version 4.0 . 4 . Known metastatic brain meningeal tumor , unless subject great 6 month definitive therapy , negative imaging study within 4 week first dose study drug clinically stable ( concomitant therapy , include supportive therapy steroid anticonvulsant medication ) respect tumor time first dose study drug . 5 . Any primary CNS GCT . 6 . Concurrent treatment anticancer therapy include cytotoxic chemotherapy , immunotherapy , radiotherapy , vaccine investigational therapy study within 3 week first dose study drug . 7 . Any major surgical procedure within 3 week prior first dose study drug . 8 . Prior therapy cMET inhibitor , include ARQ197 . 9 . Substance abuse medical , psychological social condition may , opinion Investigator , interfere subject 's participation clinical study evaluation clinical study result . 10 . Any condition unstable could jeopardize safety subject subject 's protocol compliance , include know human immunodeficiency virus , hepatitis B virus hepatitis C virus infection . 11 . Inability swallow oral medication .</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>